Abstract
Hyperinflammation and uncontrolled cytokine release, which can be seen in severe cases of COVID-19, require therapy to reduce the innate immune response without hindering necessary adaptive immune mechanisms. Here, we show results from the first in-human trials using non-invasive ultrasound stimulation of the spleen to reduce cytokine release in the context of both an acute response in healthy subjects and a chronic inflammatory condition in rheumatoid arthritis patients. Splenic ultrasound results in a reduction in TNF serum levels, as well as IL-1β and IL-8 transcript levels in monocytes. There is also a down regulation of pathways involved in TNF and IL-6 production, and IFNγ- and NFκB-regulated genes. Many of these cytokines or pathways are upregulated in COVID-19 patients. There is also a reduction in chemokine transcript levels and other components of the chemotactic response, suggesting that reduction of cellular migration may contribute to the therapeutic effects of ultrasound. There is no inhibition of the adaptive immune response with ultrasound treatment relating to antibody production. This is consistent with a pre-clinical animal model where enhanced antibody production was achieved with splenic ultrasound. Therefore, this new splenic ultrasound approach has the potential to treat acute and chronic hyper-inflammatory diseases, as it lowers cytokine levels without disrupting the normal adaptive immune response. Portable ultrasound technologies are currently being developed and translated to the clinic to treat various inflammatory disorders, with more recent efforts directed towards combatting the hyperinflammation or ‘cytokine storm’ in COVID-19 patients.
Competing Interest Statement
K.W., J.G., J.A., V.C., C.P. are employees of GE and declare that GE has filed U.S. and international patent applications describing methods, devices, and systems for precision organ-based ultrasound neuromodulation. R.S.G., D.P.Z., C.R.W.K., H.H.L are affiliated with University of Minnesota and declare that they have filed U.S. and international patent applications describing methods, devices, and systems for peripheral nerve and end-organ modulation. Feinstein authors have received research funding from GE to investigate the effects of splenic ultrasound in healthy subjects. Dr. Hubert Lim holds equity in, and serves as Chief Scientific Officer of, SecondWave Systems, which is developing wearable ultrasound stimulation technologies for end-organ and neural modulation. Mr. Daniel Zachs holds equity in, and is an employee of, SecondWave Systems. These interests for Dr. Lim and Mr. Zachs have been reviewed and managed by the University of Minnesota in accordance with its Conflict of Interest policies. All other authors declare that they have no competing interests.
Clinical Trial
NCT03548116, NCT03690466
Funding Statement
Listed authors from GE Research, Feinstein Institutes for Medical Research and North Shore University Hospital have received research funding from GE to investigate the effects of splenic ultrasound stimulation in healthy subjects. Listed authors from the University of Minnesota received funding from DARPA ElectRx Program (N660011824018).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For the splenic ultrasound study involving healthy human subjects(NCT03548116), the trial was carried out in accordance with International Conference on Harmonisation Good Clinical Practice (ICH GCP) and the United States Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 812). The protocol, informed consent form, recruitment materials, and all participant materials were submitted and approved by the Institutional Review Board (IRB) at Northwell Health. For the clinical study listed at RA patients (NCT03690466), the protocol, informed consent form, recruitment materials, and all participant materials were submitted and approved by the University of Minnesota Institutional Review Board (IRB) and monitored by CTSI in accordance with its institutionally approved monitoring plan.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data associated with this study are presented in this paper or supplemental document. The RNA-seq data presented in this paper will soon be deposited in the Gene Expression Omnibus database. Other data or methods such as that used for bioinformatic analyses or visualization are available upon reasonable request.
